Haemonetics Co. (NYSE:HAE) CEO Sells $136,493.76 in Stock

Haemonetics Co. (NYSE:HAE) CEO Christopher Simon sold 1,248 shares of Haemonetics stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $109.37, for a total value of $136,493.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Christopher Simon also recently made the following trade(s):

  • On Friday, June 7th, Christopher Simon sold 2,834 shares of Haemonetics stock. The stock was sold at an average price of $103.38, for a total value of $292,978.92.
  • On Thursday, May 23rd, Christopher Simon sold 24,412 shares of Haemonetics stock. The stock was sold at an average price of $99.39, for a total value of $2,426,308.68.
  • On Monday, May 13th, Christopher Simon sold 57,587 shares of Haemonetics stock. The stock was sold at an average price of $94.51, for a total value of $5,442,547.37.

Shares of NYSE:HAE opened at $112.11 on Friday. Haemonetics Co. has a 12-month low of $80.24 and a 12-month high of $117.56. The company has a market capitalization of $5.75 billion, a price-to-earnings ratio of 46.91, a P/E/G ratio of 2.84 and a beta of 0.67. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.44 and a quick ratio of 1.62.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Tuesday, May 7th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.06. Haemonetics had a return on equity of 18.88% and a net margin of 5.69%. The company had revenue of $249.30 million during the quarter, compared to the consensus estimate of $250.62 million. During the same period in the previous year, the company posted $0.43 earnings per share. Haemonetics’s revenue for the quarter was up 6.7% on a year-over-year basis. On average, sell-side analysts anticipate that Haemonetics Co. will post 2.93 EPS for the current year.

A number of equities research analysts recently commented on the company. Zacks Investment Research downgraded Haemonetics from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd. Barrington Research reaffirmed an “outperform” rating and set a $116.00 target price (up previously from $112.00) on shares of Haemonetics in a report on Wednesday, May 8th. Raymond James raised Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 target price for the company in a report on Tuesday, May 14th. Finally, TheStreet raised Haemonetics from a “c+” rating to a “b-” rating in a report on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $118.60.

Large investors have recently made changes to their positions in the business. Financial Gravity Companies Inc. acquired a new position in Haemonetics in the fourth quarter valued at approximately $41,000. NumerixS Investment Technologies Inc lifted its holdings in Haemonetics by 500.0% in the first quarter. NumerixS Investment Technologies Inc now owns 600 shares of the medical instruments supplier’s stock valued at $52,000 after acquiring an additional 500 shares during the period. Quadrant Capital Group LLC lifted its holdings in Haemonetics by 708.8% in the first quarter. Quadrant Capital Group LLC now owns 647 shares of the medical instruments supplier’s stock valued at $54,000 after acquiring an additional 567 shares during the period. Ffcm LLC lifted its holdings in Haemonetics by 134.4% in the fourth quarter. Ffcm LLC now owns 1,744 shares of the medical instruments supplier’s stock valued at $174,000 after acquiring an additional 1,000 shares during the period. Finally, Advisor Group Inc. raised its stake in shares of Haemonetics by 614.5% during the 4th quarter. Advisor Group Inc. now owns 2,022 shares of the medical instruments supplier’s stock worth $203,000 after buying an additional 1,739 shares during the period. 98.91% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Haemonetics Co. (NYSE:HAE) CEO Sells $136,493.76 in Stock” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://sportsperspectives.com/2019/06/16/haemonetics-co-nysehae-ceo-sells-136493-76-in-stock.html.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Story: What is Call Option Volume?

Insider Buying and Selling by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.